On August 7, 2015, the U.S. District Court for the Southern District of New York released its Amarin opinion addressing whether truthful, non-misleading off-label promotion of U.S. Food and Drug Administration (FDA)-approved...more
8/12/2015
/ Abbott Laboratories ,
Allergan Inc ,
Amarin ,
Enforcement Actions ,
False Claims Act (FCA) ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
First Amendment ,
Food and Drug Administration (FDA) ,
GlaxoSmithKline ,
Off-Label Promotion ,
Pharmaceutical Industry ,
Prescription Drugs